Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Eltrombopag Choline

FDA-approved product (tablet, oral), marketed as Alvaiz, Eltrombopag Olamine, Promacta and 1 more.

Registered studies
24
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Eltrombopag Choline
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aplastic anemia
  • Autoimmune thrombocytopenic purpura
  • Chronic hepatitis C virus infection
  • Severe aplastic anemia
  • Thrombocytopenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other systemic hemostatics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

24registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Eltrombopag Choline in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Eltrombopag Choline with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers

    NCT01830660 · start 2012-04

    Registered record
    Registry ID
    NCT01830660
    Conditions
    Healthy
    Interventions
    Hetrombopag Olamine Tablets; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-04
    Completion
    2013-06
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionHetrombopag Olamine Tablets; placebo
    PhasePhase 1
    Registry statusCompleted

  • Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

    NCT01428635 · start 2012-01-13

    Registered record
    Registry ID
    NCT01428635
    Conditions
    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Primary Myelofibrosis; Thrombocytopenia
    Interventions
    Eltrombopag Olamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2012-01-13
    Completion
    2022-01-03
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Primary Myelofibrosis +1 more
    InterventionEltrombopag Olamine
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

    NCT01147809 · start 2010-06

    Registered record
    Registry ID
    NCT01147809
    Conditions
    Thrombocytopaenia
    Interventions
    Eltrombopag olamine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-06
    Completion
    2015-03
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombocytopaenia
    InterventionEltrombopag olamine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

    NCT01098487 · start 2010-05

    Registered record
    Registry ID
    NCT01098487
    Conditions
    Purpura, Thrombocytopaenic, Idiopathic
    Interventions
    Eltrombopag olamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-05
    Completion
    2014-05
    Enrolment
    167

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPurpura, Thrombocytopaenic, Idiopathic
    InterventionEltrombopag olamine
    PhasePhase 4
    Registry statusCompleted

  • Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

    NCT00903422 · start 2009-05-14

    Registered record
    Registry ID
    NCT00903422
    Conditions
    Myelodysplastic Syndrome
    Interventions
    eltrombopag olamine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-05-14
    Completion
    2013-12-05
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndrome
    Interventioneltrombopag olamine; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)

    NCT00424177 · start 2007-03

    Registered record
    Registry ID
    NCT00424177
    Conditions
    Purpura, Thrombocytopaenic, Idiopathic
    Interventions
    eltrombopag
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-03
    Completion
    2008-11
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPurpura, Thrombocytopaenic, Idiopathic
    Interventioneltrombopag
    PhasePhase 2
    Registry statusCompleted

  • LENS - Long-term Eltrombopag Observational Study

    NCT00643929 · start 2007-02

    Registered record
    Registry ID
    NCT00643929
    Conditions
    Purpura, Thrombocytopaenic, Idiopathic
    Interventions
    Eltrombopag
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-02
    Completion
    2013-03
    Enrolment
    164

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPurpura, Thrombocytopaenic, Idiopathic
    InterventionEltrombopag
    PhaseNot recorded
    Registry statusCompleted

  • RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag

    NCT00370331 · start 2006-11

    Registered record
    Registry ID
    NCT00370331
    Conditions
    Purpura, Thrombocytopaenic, Idiopathic
    Interventions
    eltrombopag; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-11
    Completion
    2008-07
    Enrolment
    197

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPurpura, Thrombocytopaenic, Idiopathic
    Interventioneltrombopag; Placebo
    PhasePhase 3
    Registry statusCompleted

  • EXTEND (Eltrombopag Extended Dosing Study)

    NCT00351468 · start 2006-06

    Registered record
    Registry ID
    NCT00351468
    Conditions
    Purpura, Thrombocytopaenic, Idiopathic
    Interventions
    eltrombopag olamine (SB-497115-GR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-06
    Completion
    2015-07
    Enrolment
    302

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPurpura, Thrombocytopaenic, Idiopathic
    Interventioneltrombopag olamine (SB-497115-GR)
    PhasePhase 3
    Registry statusCompleted